• Establishes a dedicated, Australian-based manufacturing facility to support Gelteq's gel-based products
• Strengthens IDT's capabilities and market differentiation in pharmaceutical innovation
• Positions IDT at the forefront of an innovative drug delivery platform

IDT Australia Limited (ASX: IDT), a leading pharmaceutical contract development and manufacturing organisation (CDMO), has announced the signing of a Memorandum of Understanding (MoU) with Gelteq Limited (NASDAQ: GELS) for a dedicated, Australian-based manufacturing facility to support the development and scale-up of Gelteq's gel-based products across diverse global pharmaceutical, nutraceutical and animal health markets. Gelteq is a Nasdaq-listed clinical and science-based company focused on developing and commercialising white label ingestible gel-based solutions for prescription drugs, nutraceuticals, pet care, sports and other products. The MoU establishes a framework for Gelteq to set up its base and develop a dedicated facility within IDT's GMP manufacturing site, with both parties anticipating a final binding agreement in the coming months. This partnership will position IDT at the forefront of an innovative drug delivery platform not currently available in Australia for pharmaceuticals, expanding its suite of advanced delivery technologies for clients. With Gelteq onsite as an integral part of IDT, it equips IDT with access to enhanced capabilities, strengthens its market differentiation, and creates opportunities for collaboration, new revenue streams, and unique client offerings, reinforcing its reputation as a leader in pharmaceutical innovation.

This partnership will position IDT at the forefront of an innovative drug delivery platform not currently available in Australia for pharmaceuticals, expanding its suite of advanced delivery technologies for clients. With Gelteq onsite as an integral part of IDT, it equips IDT with access to enhanced capabilities, strengthens its market differentiation, and creates opportunities for collaboration, new revenue streams, and unique client offerings, reinforcing its reputation as a leader in pharmaceutical innovation.